---
title: "Australia's Mayne Pharma soars 13% on strong first-half earnings forecast"
date: "2025-02-10 07:43:46"
summary: "** Shares of Mayne Pharma Group soar 13.3% to A$5.30, their highest level since December 3, 2024** Stock heads for a fourth consecutive session of gains, among top gainers in the ASX All Ordinaries index (.AORD)** Speciality pharmaceutical firm says it expects 1H25 underlying EBITDA between A$30 million ($18.76 million)..."
categories:
  - "Reuters"
lang:
  - "en"
translations:
  - "en"
tags:
  - "Reuters"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

\*\* Shares of Mayne Pharma Group soar 13.3% to A$5.30, their highest level since December 3,Â 2024

\*\* Stock heads for a fourth consecutive session of gains, among top gainers in the ASX All Ordinaries index (.AORD)

\*\* Speciality pharmaceutical firm says it expects 1H25 underlying EBITDA between A$30 million ($18.76 million) and A$32 million, up to four-fold jump from last year's A$8 million

\*\* Revenue forecast between A$210 million and A$215 million, up to 14% growth

\*\* Co expects to see continued growth in 2H25

\*\* More than 112,000 shares change hands, vs the 30-day average of about 95,000 shares

\*\* MYX up 6.8% this year, including day's moves

($1 = 1.5995 Australian dollars)

[Reuters](https://www.tradingview.com/news/reuters.com,2025:newsml_L4N3P004J:0-australia-s-mayne-pharma-soars-13-on-strong-first-half-earnings-forecast/)
